Leaderboard

En | De
No articles selected!     View Cart  
You are here: Dermatology » Skin Neoplasms 10. July 2020
Search
medline.ch
Skin Neoplasms
Advanced search
Dermatology
Acne
Alopecia
Dermatitis
Infectious Skin Diseases
Photosensitivity Disorder
Psoriasis
Skin Neoplasms
Melanoma
Others
Skin Ulcer
Urticaria
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Zoom: Zoom In Zoom Out

   Page 1 of 5344  Previews Next
   
   Articles 1 - 20 / 106867  
   
Impact of Non-steroidal Anti-inflammatory Drugs on Recurrence and Survival after Melanoma Surgery: A Cohort Study.
Cancer Invest
Araujo BLC, de Oliveira JL, Rezende JFN, Noguera WS, de Melo AC, Thuler LCS.
PMID: 32643437 [PubMed - as supplied by publisher]


Oncology Nurse Coordinators in Clinical Trials - Shaking up the Melanoma Team.
Asia Pac J Oncol Nurs
Steinberg H.
PMID: 32642495 [PubMed]


Acral Lentiginous Melanoma: A Rare Variant With Unique Diagnostic Challenges.
Cureus
Brazen BC, Gray T, Farsi M, Miller R.
PMID: 32642340 [PubMed]


Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities.
Dermatol Pract Concept
Forsea AM.
PMID: 32642304 [PubMed]


T-cell receptor therapy (TCR) against melanoma -immunotherapy for the future?
Scand J Immunol
Winge-Main AK, Wälchli S, Marit Inderberg E.
PMID: 32640053 [PubMed - as supplied by publisher]


Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.
Nat Rev Clin Oncol
Robert C, Marabelle A, Herrscher H, Caramella C, Rouby P, Fizazi K, Besse B.
PMID: 32636502 [PubMed - as supplied by publisher]


Reporting regression with melanoma in situ: reappraisal of a potential paradox.
Arch Dermatol Res
Cartron AM, Aldana PC, Khachemoune A.
PMID: 32632620 [PubMed - as supplied by publisher]


Consensus Guidelines for the Management of Melanoma during the COVID-19 Pandemic: Surgery, Systemic Anti-cancer Therapy, Radiotherapy and Follow-up.
Clin Oncol (R Coll Radiol)
Nahm SH, Rembielak A, Peach H, Lorigan PC, Contributing Clinicians..
PMID: 32631767 [PubMed - as supplied by publisher]


Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma.
Cancers (Basel)
Chillà A, Margheri F, Biagioni A, Del Rosso T, Fibbi G, Del Rosso M, Laurenzana A.
PMID: 32630815 [PubMed]


Chitosan-Based Delivery of Avian Reovirus Fusogenic Protein p10 Gene: In Vitro and In Vivo Studies towards a New Vaccine against Melanoma.
Biomed Res Int
Robles-Planells C, Barrera-Avalos C, Rojo LE, Spencer E, Cortez-San Martin M, Matiacevich S, Pavez J, Milla LA, Navarro FD, Martínez BA, Bravo FJ, Mella A, Huidobro-Toro JP, Fernandez R, Escobar A, Castillo CA.
PMID: 32626742 [PubMed - in process]


Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Front Cell Dev Biol
Yeon M, Kim Y, Jung HS, Jeoung D.
PMID: 32626712 [PubMed]


The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years.
Ann Surg Oncol
Moncrieff MD, Underwood B, Garioch JJ, Heaton M, Patel N, Bastiaannet E, Hoekstra-Weebers JEHM, Hoekstra HJ.
PMID: 32623608 [PubMed - as supplied by publisher]


A Retrospective Multicenter Study of Fatal Pediatric Melanoma.
J Am Acad Dermatol
Hawryluk EB, Moustafa D, Bartenstein D, Brahmbhatt M, Cordoro K, Gardner L, Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao PC, Kruse LL, Lawley LP, London WB, Mansour D, O'Haver JA, Phung T, Pope E, Price HN, Rogers T, Shah SD, Wolner Z, Huang J, Marghoob AA.
PMID: 32622142 [PubMed - as supplied by publisher]


Early Phase of Primary Melanoma Growth from the Patient Point of view: A Prospective Cross Sectional Study on Melanoma over 1 mm in Thickness.
Acta Derm Venereol
Malissen N, Abed S, Macagno N, Amatore F, Loundou A, Grange F, Gaudy-Marqueste C, Grob JJ.
PMID: 32618351 [PubMed - as supplied by publisher]


Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations.
Ther Adv Med Oncol
Giunta EF, De Falco V, Napolitano S, Argenziano G, Brancaccio G, Moscarella E, Ciardiello D, Ciardiello F, Troiani T.
PMID: 32612709 [PubMed]


Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.
Cancers (Basel)
Lebbé C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dréno B.
PMID: 32610581 [PubMed]


Characterization of uveal melanoma clinical trial design: a systematic review to establish an elusive standard of care.
Acta Oncol
Zhang HG, Moser JC, Dalvin LA.
PMID: 32609032 [PubMed - as supplied by publisher]


Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: a population-based case-control study.
Basic Clin Pharmacol Toxicol
Daniels B, Pearson SA, Vajdic CM, Pottegård A, Buckley NA, Zoega H.
PMID: 32608576 [PubMed - as supplied by publisher]


KIT and Melanoma: Biological Insights and Clinical Implications.
Yonsei Med J
Pham DDM, Guhan S, Tsao H.
PMID: 32608199 [PubMed - in process]


Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study.
J Immunother Cancer
Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H.
PMID: 32606047 [PubMed - in process]


   
   Articles 1 - 20 / 106867    Page 1 of 5344  Previews Next

 
Rect Bottom
Adserver Footer
 

Username

Password

 

 

Forgot your username or password?

 

New User? Sign Up

Register to My Medline!

 

Learn more about the My Medline experience

more >>

  Time frame  
   

Sky right 1